Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/01/24
End: 03/01/25
Due: 03/01/26
Phase: N/A
Priority: Normal
Start: 11/06/20
End: 06/01/25
Due: 06/01/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | NCT05974410 | AVM Biotechnology Inc | user2@example.com | None | - | - | - | - | - | 2025-07-14 |
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS | NCT04366115 | AVM Biotechnology Inc | user2@example.com | None | 2024-12-01 | 2025-03-01 | 2026-03-01 | - | - | 2025-07-14 |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | NCT04329728 | AVM Biotechnology Inc | user2@example.com | None | 2020-11-06 | 2025-06-01 | 2026-06-01 | - | - | 2025-07-14 |